Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Palovarotene in Multiple Osteochondromas
2017-002751-28Phase 2Terminated
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of palovarotene in osteochondromatosis (3 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoint: Annualized rate of new osteochondromas. Started Aug 2018; status: terminated.
02
Drugs
palovarotene
03
Conditions
osteochondromatosis
Beyond the preview
Go deeper on 2017-002751-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002751-28.